Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward J Cone

Showing results (11-20 of 107) with videos related to

Pageof 11
Sort By:
Journal of Analytical Toxicology|November 2, 2004
Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabisMarilyn A Huestis, Edward J Cone
Journal of Analytical Toxicology|November 9, 2007
Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluidEdward J Cone, Joe Clarke, Lolita Tsanaclis
Drug and Alcohol Dependence|January 22, 2013
An iterative model for in vitro laboratory assessment of tamper deterrent formulationsEdward J Cone, Jennifer Giordano, Brianne Weingarten
Pain Practice : the Official Journal of World Institute of Pain|September 8, 2016
Striving for Consensus on Approaches to Category 1 Testing of Abuse-Deterrent Formulations of Opioids: Discussions from the First Category 1 Focus Group MeetingEdward J Cone, Marta Sokolowska, Karsten Lindhardt
Journal of Analytical Toxicology|November 11, 2003
Caffeine content of specialty coffeesRachel R McCusker, Bruce A Goldberger, Edward J Cone
Therapeutic Drug Monitoring|May 21, 2005
Relationship between plasma and oral fluid nicotine concentrations in humans: a pilot studyAmanda J Jenkins, Jack E Henningfield, Edward J Cone
Journal of Analytical Toxicology|April 20, 2006
Caffeine content of energy drinks, carbonated sodas, and other beveragesRachel R McCusker, Bruce A Goldberger, Edward J Cone
Postgraduate Medicine|December 6, 2016
Current and future development of extended-release, abuse-deterrent opioid formulations in the United StatesLynn R Webster, John Markman, Edward J Cone, et al.
Postgraduate Medicine|November 12, 2014
Risks and responsibilities in prescribing opioids for chronic noncancer pain, part 2: best practicesEdward J Cone, Anne Z DePriest, Allan Gordon, et al.
Journal of Clinical Psychopharmacology|September 7, 2004
Effects of high-dose intravenous buprenorphine in experienced opioid abusersAnnie Umbricht, Marilyn A Huestis, Edward J Cone, et al.
Pageof 11

Showing results (11-20 of 107) with videos related to

Sort By:
Pageof 11
Journal of Analytical Toxicology|November 2, 2004
Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabisMarilyn A Huestis, Edward J Cone
Journal of Analytical Toxicology|November 9, 2007
Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluidEdward J Cone, Joe Clarke, Lolita Tsanaclis
Drug and Alcohol Dependence|January 22, 2013
An iterative model for in vitro laboratory assessment of tamper deterrent formulationsEdward J Cone, Jennifer Giordano, Brianne Weingarten
Pain Practice : the Official Journal of World Institute of Pain|September 8, 2016
Striving for Consensus on Approaches to Category 1 Testing of Abuse-Deterrent Formulations of Opioids: Discussions from the First Category 1 Focus Group MeetingEdward J Cone, Marta Sokolowska, Karsten Lindhardt
Journal of Analytical Toxicology|November 11, 2003
Caffeine content of specialty coffeesRachel R McCusker, Bruce A Goldberger, Edward J Cone
Therapeutic Drug Monitoring|May 21, 2005
Relationship between plasma and oral fluid nicotine concentrations in humans: a pilot studyAmanda J Jenkins, Jack E Henningfield, Edward J Cone
Journal of Analytical Toxicology|April 20, 2006
Caffeine content of energy drinks, carbonated sodas, and other beveragesRachel R McCusker, Bruce A Goldberger, Edward J Cone
Postgraduate Medicine|December 6, 2016
Current and future development of extended-release, abuse-deterrent opioid formulations in the United StatesLynn R Webster, John Markman, Edward J Cone, et al.
Postgraduate Medicine|November 12, 2014
Risks and responsibilities in prescribing opioids for chronic noncancer pain, part 2: best practicesEdward J Cone, Anne Z DePriest, Allan Gordon, et al.
Journal of Clinical Psychopharmacology|September 7, 2004
Effects of high-dose intravenous buprenorphine in experienced opioid abusersAnnie Umbricht, Marilyn A Huestis, Edward J Cone, et al.
Pageof 11